[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"phototherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:phototherapy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,78,109,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644802","bilirubin-thresholds-in-preterm-infants-on-neonatal-intensive-care-units-the-b-nice-trial-100644802",false,"NCT07674537","Bilirubin Thresholds in Preterm Infants on Neonatal Intensive CarE Units: The B-NICE Trial","B-NICE","Inclusion Criteria:\n\n* Gestational age at birth \\\u003C30+0 weeks.\n* Admission to a participating NICU within 24 hours after birth.\n* Parental consent according to the approved consent procedure\n\nExclusion Criteria:\n\n* Major congenital anomalies, excluding intraventricular hemorrhage, expected to affect survival or neurodevelopmental outcome.\n* Antenatal diagnosis of immune hemolytic disease of the fetus or newborn (such as RhD antagonism) requiring protocolized alternative management.","ALL","24 Weeks","29 Weeks",{"count":20,"type":21},680,"ESTIMATED","INTERVENTIONAL",[24],"NA","Rationale: Neonatal hyperbilirubinemia is highly prevalent in very preterm infants born \\\u003C30 weeks. Since 2008, uniform Dutch phototherapy thresholds for preterm infants have been used nationwide, largely based on consensus. Consequently, \\>80% of very preterm infants receive phototherapy for several days, accompanied by repeated blood sampling and reduced opportunities for skin-to-skin care. The corresponding UK National Institute for Health and Care Excellence (NICE) guideline applies higher (less strict) thresholds, which may reduce overtreatment, but comparative safety for very preterm infants has not been established in a randomized trial. The investigators hypothesize that using NICE thresholds is non-inferior to Dutch thresholds for survival without neurodevelopmental impairment (NDI) at two years' corrected age, while reducing treatment burden.\n\nObjective: Primary: To determine whether initiating phototherapy according to NICE thresholds is non-inferior to Dutch thresholds with regard to survival without NDI at two years' corrected age in infants born \\\u003C30 weeks of gestation. Secondary: To compare phototherapy exposure (incidence, duration and cumulative exposure) and monitoring burden (e.g., number of bilirubin blood samples, temperature instability, biomarkers of oxidative stress (subpopulation)), and to evaluate parent-infant outcomes (skin-to-skin contact time, parental stress\u002Fsatisfaction), and nursing workload (time dedicated to bilirubin-related care).\n\nStudy design: Nationwide multicenter, parallel-group, open-label randomized non-inferiority trial with 1:1 allocation, stratified by center and gestational age category (\\\u003C28 weeks and ≥28 weeks). Follow-up continues to the routine neurodevelopmental assessment at two years' corrected age. Planned project duration: 36 months.\n\nStudy population: Very preterm infants born \\\u003C30+0 weeks of gestation, admitted to a participating Dutch NICU within 24 hours after birth.\n\nIntervention: Bilirubin monitoring and phototherapy according to one of two threshold strategies: (1) current Dutch phototherapy thresholds (control) or (2) thresholds from the UK NICE guideline (intervention). Phototherapy is delivered using standard NICU devices.\n\nMain study parameters\u002Fendpoints: Primary endpoint: survival without NDI at two years' corrected age. NDI is defined as Bayley Scales of Infant and Toddler Development, fourth Edition, Dutch Version (BSID-IV-NL) cognitive and\u002For motor composite score \\\u003C85 and\u002For hearing impairment and\u002For visual impairment.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Both strategies reflect accepted standards of care with routine bilirubin monitoring. Incremental burden consists mainly of additional registration (phototherapy use, bilirubin sampling, skin-to-skin contact, temperature instability), parental questionnaires and, in selected centers, collection of stress-related biomarkers from urine, feces, or waste material from routine blood samples to explore the physiological impact of phototherapy. No biobanking for future unspecified research is planned. The investigators will also use routinely collected and stored monitor data to assess sleep (sleep-wake states and sleep fragmentation) in a subset of infants. Neurodevelopmental follow-up at two years corrected age is routine care in Dutch NICUs. Bilirubin levels above thresholds in both groups will be mitigated by routine monitoring and management according to this study protocol. The study is group-related because bilirubin management and potential neurotoxicity thresholds are specific to very preterm infants.",[27,28,29,30,31],"Neonatal Hyperbilirubinemia","Treatment Decisions","Neurodevelopmental Outcome","Phototherapy","Exchange Transfusion",[33,34],"neonatal jaundice","preterm infants \u003C 30 weeks GA","NOT_YET_RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":21},"2026-08-01",{"date":43,"type":21},"2029-11-01",{"name":45,"class":46},"University Medical Center Groningen","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100638745","light-therapy-to-improve-sleep-in-tbi-sleep-active-biomarkers-and-glymphatic-function-100638745","NCT07601841","Light Therapy to Improve Sleep in TBI: Sleep-active Biomarkers and Glymphatic Function","Light Therapy to Improve Sleep in Veterans With TBI: Sleep-active Biomarkers and Glymphatic Function","GLIMPSE-LION","All subjects must:\n\n1. Male and female; any race; 18-89 years of age.\n2. Be English speaking.\\*\n3. Be accessible via phone.\n4. Be non-decisionally impaired. Determined by assessing the subject's ability to verbalize their understanding of the protocol back to us during the informed consent process.\n5. Not have a history of macular degeneration.\n6. Not have a history of bipolar disorder.\n7. Not be currently using a lightbox or a negative ion generator.\n8. Not be a shift worker.\n9. Have a documented history of TBI via the Head Trauma Events Characteristics (HTEC) or OHIO conducted in accordance with VA\u002FDoD Clinical Practice Guidelines.88\n10. Present with self-reported sleep-wake disturbances.\n11. Remain clinically stable for current pharmacologic treatment related to depression\u002Fanxiety, sleep, and pain.\n12. MRI specific compatibility requirements:\n\n    * No pacemaker, wires, defribrillator or implanted heart valves\n    * No history of head surgery requiring aneurysm clips\n    * No history of other orthopedic or general surgery requiring the implantation of ferrous pins, joints, electric devices\u002Fpumps, or other foreign metal objects\n    * History of eye exposure to metal (unprotected welding\u002Fmetalworking\u002Fshrapnel) is allowable provided the participant screens negative for metal in the eyes on an orbital x-ray or is able to provide clinical documentation of having screened negative.\n    * No history of non-removable hearing aids, middle\u002Finner ear prosthesis, or dentures\n    * No history of claustrophobia; if unsure participant will be pre-screened in our mock scanner\n    * Not currently pregnant, breastfeeding, or have an implanted IUD. Participants who are unsure of their pregnancy status will be administered an hCG urine pregnancy test the day of their scan.\n    * Able to lay flat on their back comfortably without a thick pillow for an extended period of time.\n    * Shoulder width does not exceed width for safety fitting in the MRI bore.\n\n      * This study is limited to English-speaking participants because all assessments, interventions, and consent materials are currently validated and approved only in English. Expanding to other languages would require translation and psychometric validation, which are beyond the scope and budget of this study. This limitation is acknowledged and will be addressed in future research as resources permit. Finally, the study team is only fluent in English, making it infeasible to accurately consent or interact with non-English speakers without interpreting services which again is outside of the scope of this projects budget and timeline. Proceeding without formal translation services would risk miscommunication in informed consent, data collection, or participant support and thus protects participants informed consent and participant understanding.","18 Years","89 Years",{"count":59,"type":21},300,[24],"This is a clinical trial designed to examine how improved sleep through morning bright light therapy is improving downstream key physiologic processes related to brain health, i.e., mitochondrial function, systemic inflammation, and glymphatic function. All proposed methodology is already approved in other IRB applications.",[63,30,64,65,66,67],"Sleep","Glymphatic System","Mitochondrial Dynamics","Brain Injuries, Traumatic","Inflammation","RECRUITING","2026-05-18",{"date":71,"type":39},"2026-05-22",{"date":73,"type":39},"2025-12-12",{"date":75,"type":21},"2030-09-30",{"name":77,"class":46},"Oregon Health and Science University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":56,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100632293","photobiomodulation-on-recovery-in-female-futsal-athletes-100632293","NCT07511803","Photobiomodulation on Recovery in Female Futsal Athletes","Effects of Photobiomodulation Therapy on Recovery After Exercise in Female Futsal Athletes","PBMT","Inclusion Criteria:\n\n* Women aged 18-35 years\n* Be a futsal athlete for at least 2 years\n\nExclusion Criteria:\n\n* Users of tobacco products\n* Use of nutritional supplements or anabolic steroid hormones for at least 6 months prior to the study",true,"FEMALE","35 Years",{"count":90,"type":21},15,[24],"The aim of this study is to investigate the effects of photobiomodulation therapy (PBMT) on recovery after high-intensity, intermittent exercises in female futsal athletes. It is hypothesized that PBMT is superior to placebo condition in improving the recovery of muscle function after high-intensity, intermittent exercises.",[94,95,30,96],"Muscle Recovery","Exercise","Futsal",[98,95,30,99],"Muscle recovery","futsal","2026-03-30",{"date":102,"type":39},"2026-04-06",{"date":104,"type":21},"2026-04-15",{"date":106,"type":21},"2026-06-10",{"name":108,"class":46},"Universidade Norte do Paraná",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":84,"eligibilityCriteria":115,"healthyVolunteers":86,"sex":87,"minAge":56,"maxAge":88,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":127,"locationsCount":4},"100632292","photobiomodulation-on-performance-in-female-futsal-athletes-100632292","NCT07511790","Photobiomodulation on Performance in Female Futsal Athletes","Effects of Photobiomodulation Therapy on Physical Performance in Female Futsal Athletes","Inclusion Criteria:\n\n* Women aged 18-35 years.\n* Futsal athlete for at least 2 years.\n\nExclusion Criteria:\n\n* Users of tobacco products\n* Use of nutritional supplements or anabolic steroid hormones for at least 6 months prior to the study.",{"count":90,"type":21},[24],"The aim of this study is to investigate the effects of photobiomodulation therapy (PBMT) on physical performance in female futsal athletes. It is hypothesized that PBMT is superior to placebo condition in improving the ability to perform repeated sprints and aerobic capacity in high-intensity, intermittent activity (i.e., Bangsbo sprint test and yoyo intermittent recovery level-1, respectively).",[120,95,30,96],"Muscle Performance",[122,95,30,123],"Muscle performance","Futsal athletes",{"date":102,"type":39},{"date":104,"type":21},{"date":106,"type":21},{"name":108,"class":46},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":86,"sex":16,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":47},"100524575","violet-light-for-the-suppression-of-myopia-100524575","NCT06110520","Violet Light for the Suppression of Myopia","Violet Light for Treatment of Myopia","Inclusion Criteria:\n\n* Children must be between 5 to \\\u003C13 years old.\n* Diagnosis of Myopia (ICD-10-CM Diagnosis\n\nCode H52.13) with refractive error:\n\n1. Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes\n2. Astigmatism \\\u003C=1.50D in both eyes\n3. Anisometropia \\\u003C=1.00D SE • Relocation outside of the CCHMC area within the next 12 months is not anticipated.\n\nExclusion Criteria:\n\nCurrent or previous myopia treatment with atropine, pirenzepine, or other antimuscarinic agents\n\n* Current or previous use of bifocals, progressive addition lenses, or multi-focal contact lenses\n* Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression\n* Current or prior history of manifest strabismus, amblyopia, or nystagmus\n* Abnormality of cornea, lens, central retina, iris, or ciliary body\n* Prior eyelid, strabismus, intraocular, or refractive surgery\n* Down syndrome or cerebral palsy","5 Years","12 Years",{"count":138,"type":21},72,[24],"The study explores the suppression of myopia via violet light.",[142,30],"Myopia",[142,144],"Violet Light","2025-12-16",{"date":147,"type":39},"2025-12-22",{"date":149,"type":39},"2023-06-07",{"date":151,"type":21},"2028-01-01",{"name":153,"class":46},"Children's Hospital Medical Center, Cincinnati"]